Vera reported 700 patient start forms for Trutacna, described its early launch in the United States as strong, and plans to file in Europe in the first quarter of next year.
VERA · Vera Therapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Vera Therapeutics reported $10.3 million in Trutacna revenue and approximately 700 patient start forms. It submitted an SBLA seeking full FDA approval, anticipated in mid-2027, supported by a 76% reduction in kidney disease progression risk through 104 weeks.
Vera Therapeutics’ TRUTAKNA received FDA accelerated approval on July 7, 2026, for adults with primary IgAN at risk for progression; it generated $10.3 million in product revenue through September 30, 2026, while requesting full approval on November 3, 2026.
Vera Therapeutics reported $10.3 million in TRUTAKNA revenue; approximately 700 Patient Start Forms were received. ORIGIN 3 showed a 76% reduction in progression risk versus placebo through two years, and an sBLA was submitted to the FDA for full approval.
Vera Therapeutics reported a 76% reduction in composite kidney progression through week 104 and an annualized eGFR difference of 5 mL per minute per year for atachycept. An FDA submission supporting potential full approval is planned for 2027.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Debt facility availability | $350M | as of November 5, 2026 | — |
| Patient Start Forms (PSFs) | 700 | to date following TRUTAKNA's accelerated approval | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VERA
this stock
Vera Therapeutics, Inc.
|
$1.93B | -47.2% | — | — | 16.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 20
Vera reported 700 patient start forms for Trutacna, described its early launch in the United States as strong, and plans to file in Europe in the first quarter of next year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VERA | -7.9% | -7.9% | -21.2% | -13.7% | -47.2% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -2.4% | -1.6% | -15.6% | -8.4% | -52.2% |